Sign in
CompletedNo phase

Collagen-based Filler for Trapeziometacarpal Osteoarthritis

Key facts

Who runs it
Azienda Ospedaliera Universitaria Integrata Verona
Where
Italy1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
64 people enrolled
Started
1 Jan 2021
Ended
1 Jan 2025
Type of study
Observational
Treatments tested
  • Intra-articular injection
Record updated
18 March 2025

Who can take part

Age
18 years to 99 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (9)Hide the full registry criteria

Who can take part

  • patients with rhizarthrosis diagnosed on X-rays performed in the last year
  • patients aged > 18 years
  • enrollment in the study through informed consent

Who cannot take part

  • patients with underlying rheumatological diseases
  • patients affected by metabolic disorders (e.g. diabetes)
  • patients under 18 years of age
  • patients who have undergone cortisone and/or hyaluronic acid infiltrations in the last 6 months
  • patients following trauma involving the ATM
  • ongoing pregnancy

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Introduction. Trapeziometacarpal osteoarthritis (TMC OA) is a degenerative condition characterized by pain, stiffness, and reduced hand function, significantly impairing daily activities. Non-surgical management strategies include activity modifications, nonsteroidal anti-inflammatory drugs (NSAIDs), splinting, and corticosteroid injections. When conservative treatments fail, surgical options are considered. The Eaton-Littler classification stratifies TMC OA into four stages based on radiographic joint degeneration.

Read full original descriptionShow less

ChondroFiller Liquid®, a cell-free collagen scaffold composed of native type I collagen and chondrostimulating factors, facilitates cartilage regeneration by creating a protective environment for chondrocyte proliferation. It is indicated for treating cartilage lesions up to 3 cm². A prior study demonstrated its efficacy in alleviating pain, improving grip strength (Jamar test and pinch test), and enhancing Patient-Reported Outcome Measures (PROMs) using the Disabilities of the Arm, Shoulder, and Hand (DASH) score.

Aims. This study aims to extend the follow-up to 24 months to evaluate the long-term sustainability of clinical improvements following ChondroFiller Liquid® infiltration.

Materials and Methods. A total of 40 patients from the initial study were enrolled and categorized into two severity groups based on the Eaton-Littler classification. Clinical evaluations were conducted at 18 months post-infiltration (T1) using the Numeric Rating Scale (NRS) and DASH score. A subsequent assessment at 24 months (T2) included the Jamar test, pinch test, NRS, and DASH score. An additional cohort of 51 patients underwent infiltration with a mean follow-up of 14 months, including 9 patients previously treated in the preliminary study.

Treatments tested

  • Intra-articular injection

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Use of Collagen-based Filler for Trapeziometacarpal Osteoarthritis. Long-term Follow Up and Future Applications
Publications
Record updated
18 March 2025